Bukwang, BMS Korea set to challenge GSK's hepatitis B medicines in second quarter

Published: 2008-02-26 06:59:00

Updated: 2008-02-26 06:59:00

Domestic hepatitis B market is heating up as Bukwang Pharm's Levovir (clevudine) and BMS Korea's Baraclude (entecavir) are poised to snatch up a large share of GlaxoSmithKline's Zeffix (lamivudine) and Hepsera (adefovir) in the second quarter of this year, according to sources.

The domestic anti-hepatitis B market is estimated to be worth 120 billion won and expected to be further expanded a...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.